L-Dopa-induced dyskinesias Nicotine Nicotinic receptors Parkinson's disease L-Dopa-induced dyskinesias (LIDs) are abnormal involuntary movements that develop with long term L-dopa therapy for Parkinson's disease. Studies show that nicotine administration reduced LIDs in several parkinsonian animal models. The present work was done to understand the factors that regulate the nicotine-mediated reduction in LIDs in MPTP-lesioned nonhuman primates. To approach this, we used two groups of monkeys, one with mild-moderate and the other with more severe parkinsonism rendered dyskinetic using L-dopa. In mildmoderately parkinsonian monkeys, nicotine pretreatment (300 μg/ml via drinking water) prevented the development of LIDs by~75%. This improvement was maintained when the nicotine dose was lowered to 50 μg/ml but was lost with nicotine removal. Nicotine re-exposure again decreased LIDs. By contrast, nicotine treatment did not reduce LIDs in monkeys with more severe parkinsonism. We next determined how nicotine's ability to reduce LIDs correlated with lesion-induced changes in the striatal dopamine transporter and 3 H-dopamine release in these two groups of monkeys. The striatal dopamine transporter was reduced to 54% and 28% of control in mild-moderately and more severely parkinsonian monkeys, respectively. However, basal, K + , α4β2* and α6β2* nAChR-evoked 3 H-dopamine release were near control levels in striatum of mild-moderately parkinsonian monkeys. By contrast, these same release measures were reduced to a significantly greater extent in striatum of more severely parkinsonian monkeys. Thus, nicotine best improves LIDs in lesioned monkeys in which striatal dopamine transmission is still relatively intact. These data suggest that nicotine treatment would most effectively reduce LIDs in patients with mild to moderate Parkinson's disease.
L-Dopa-induced dyskinesias (LIDs) are abnormal involuntary movements that develop with long term L-dopa therapy for Parkinson's disease. Studies show that nicotine administration reduced LIDs in several parkinsonian animal models. The present work was done to understand the factors that regulate the nicotine-mediated reduction in LIDs in MPTP-lesioned nonhuman primates. To approach this, we used two groups of monkeys, one with mild-moderate and the other with more severe parkinsonism rendered dyskinetic using L-dopa. In mildmoderately parkinsonian monkeys, nicotine pretreatment (300 μg/ml via drinking water) prevented the development of LIDs by~75%. This improvement was maintained when the nicotine dose was lowered to 50 μg/ml but was lost with nicotine removal. Nicotine re-exposure again decreased LIDs. By contrast, nicotine treatment did not reduce LIDs in monkeys with more severe parkinsonism. We next determined how nicotine's ability to reduce LIDs correlated with lesion-induced changes in the striatal dopamine transporter and 3 H-dopamine release in these two groups of monkeys. The striatal dopamine transporter was reduced to 54% and 28% of control in mild-moderately and more severely parkinsonian monkeys, respectively. However, basal, K + , α4β2* and α6β2* nAChR-evoked
Introduction
The dopamine precursor L-dopa is the primary treatment for the motor symptoms associated with Parkinson's disease (PD). This debilitating neurodegenerative disorder is characterized by tremor, rigidity, bradykinesia and postural instability, which are thought to be due to a loss of nigrostriatal dopaminergic neurons (Halliday et al., 2011; Meissner et al., 2011; Obeso et al., 2010; Rascol et al., 2011; Schapira, 2009; Schapira and Jenner, 2011; Wichmann et al., 2011) . L-dopa treatment ameliorates motor deficits because of its ability to elevate nigrostriatal dopamine levels. However, in addition to improving parkinsonian features, L-dopa is also associated with the emergence of side effects including abnormal involuntary movements or L-dopa-induced dyskinesias (LIDs). These develop in a significant proportion of Parkinson's disease patients receiving L-dopa treatment and represent a substantial problem with long term therapy. Current treatment strategies are limited and include a decrease in L-dopa dosing which has the disadvantage that there is a return of parkinsonian features, adjunct therapy with amantadine which has only limited effectiveness or surgical intervention (Brotchie and Jenner, 2011; Iravani and Jenner, 2011; Sankar and Lozano, 2011) .
There is therefore a critical need for therapeutic approaches to treat this debilitating side effect of L-dopa administration for PD. Recent studies show that nicotine treatment attenuates LIDs in parkinsonian nonhuman primates, when given either before the onset of dyskinesias or when they are established (Quik et al., 2007) . Nicotine also reduced L-dopa-induced abnormal involuntary movements in rodents, when given via several modes of administration, including drinking water, minipumps or injection (Bordia et al., 2008 (Bordia et al., , 2010 Huang et al., 2011a Huang et al., , 2011b .
An important question is the mechanism whereby nicotine alleviates LIDs as this may help in developing optimal therapeutic interventions. The effect of nicotine in the CNS is generally mediated via nicotinic acetylcholine receptors (nAChRs). These are ion channels composed of five subunits, with the predominant subtypes in the striatum being the α4β2* and α6β2* receptor populations (the asterisk indicates
